Scinai Immunotherapeutics Ltd. (SCNI) 股票分析

公司概述

Scinai Immunotherapeutics Ltd. is a biopharmaceutical entity dedicated to the development, manufacturing, and commercialization of biological products designed to treat infectious and autoimmune diseases within the Israeli market. The company operates within the healthcare sector, specifically focusing on the biotechnology industry, where its core innovation lies in engineering nanosized VHH antibodies, also known as nanoAbs, to target specific disease pathways. As of the latest reporting period, the company maintains a market capitalization of $2.05 million and reports trailing twelve-month revenue of $1.31 million, while its employee count is listed as unavailable. These valuation and revenue figures indicate that Scinai operates as a small-cap entity with a relatively modest revenue base, suggesting it is in an early-stage commercialization phase typical for biotechnology firms focused on specialized therapeutic assets rather than established mass-market products.

财务健康

The company reported trailing twelve-month revenue of $1.31 million against a net income of -$8,307,000 and an EBITDA of -$6,121,000, revealing a significant structural gap where operating expenses substantially exceed generated revenue. This disparity indicates a high burn rate characteristic of biotechnology companies investing heavily in research and development and clinical trial costs before achieving commercial profitability. Free cash flow stands at -$3,408,750, which implies that the company is currently consuming cash reserves to fund its operations and cannot yet generate positive cash flow from its core business activities. The company holds $1.66 million in cash assets while carrying $2.27 million in debt, resulting in a debt-to-equity ratio of 27.98 that reflects a leveraged balance sheet rather than a conservative one. Furthermore, the gross margin is recorded at -202.3%, the operating margin at -702.4%, and the profit margin at 0.0%, figures that collectively demonstrate that the cost of goods sold and operating expenses are not only exceeding revenue but doing so at rates that drive negative profitability across all operational layers. The current ratio is 1.30, indicating that the company possesses $1.30 in current assets for every $1.00 of current liabilities, which suggests a moderate ability to meet short-term obligations despite the overall negative earnings environment. Return on equity is -91.9% and return on assets is -37.6%, metrics that reveal that management has not yet generated positive returns on its shareholders' capital or asset base, a common trait for companies in the pre-revenue or early-revenue stages of the biotechnology lifecycle.

估值评估

The trailing twelve-month P/E ratio and forward P/E ratio are both listed as N/A, which implies that traditional earnings-based valuation multiples are not applicable due to the company's lack of positive earnings and the inability to calculate a meaningful forward multiple without projected income. The price-to-book ratio stands at 0.39, indicating that the market values the company at less than one-third of its net book value, suggesting that investors are pricing in significant risks or a lack of tangible asset backing relative to its equity structure. Alternative valuation metrics such as the price-to-sales ratio of 1.56 and an EV/EBITDA of -1315.56 are utilized to assess value, where the high P/S ratio relative to a small market cap suggests the market is assigning a premium to potential future sales growth despite current losses, while the negative EV/EBITDA confirms that the company has not yet achieved operational profitability to justify a standard enterprise value multiple. The 52-week trading range spans from a low of $0.55 to a high of $6.18, and without a specific current price provided in the facts, the valuation assessment relies on these bounds to contextualize potential volatility, though the current price position relative to this range cannot be mathematically determined from the available data alone. The beta value is listed as N/A, meaning that the company's historical price volatility relative to the broader market index cannot be quantified, which is typical for small-cap biotechnology stocks that often exhibit idiosyncratic risk patterns distinct from large-cap equities.

Growth & Income

Revenue growth year-over-year is recorded at 30.6%, whereas earnings growth is N/A, indicating that while the company is successfully expanding its top line, it has not yet reached a stage where earnings growth can be measured or is still negative. Since the company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it follows a strategy of reinvesting all available earnings and cash flow back into research and development rather than distributing income to shareholders. This reinvestment approach is standard for biotechnology firms aiming to advance their pipeline of nanosized VHH antibodies and secure regulatory approvals before expecting significant shareholder returns. The overall growth and income profile reflects a high-growth, zero-income trajectory typical of early-stage biotechnology companies that prioritize capital expenditure on product development over current profitability or dividend distribution.